 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Cyclophosphamide To Treat Patients with Scleroderma Lung Disease
20 June 2000 | Volume 132 Issue 12 | Page 947
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis." It is in the 20 June 2000 issue of Annals of Internal Medicine (volume 132, pages 947-954). The authors are B. White, W.C. Moore, F.M. Wigley, H.Q. Xiao, and R.A. Wise.
What is the problem and what is known about it so far?
Scleroderma is a disease of unknown cause that produces fibrosis (hardening or scarring) of the connective tissue in the skin, blood vessels, and internal organs. This results in a tight, shiny appearance of the skin and potentially life-threatening abnormalities of the lungs, heart, kidneys, and digestive tract. Scleroderma lung disease is difficult to treat. Lung inflammation (alveolitis) occurs before lung scarring (fibrosis). Cyclophosphamide is a drug that decreases inflammation; therefore, it may be useful in treating patients with scleroderma lung disease.
Why did the researchers do this particular study?
To find out whether patients with scleroderma lung disease who receive cyclophosphamide have better lung function and live longer than patients who do not get this drug.
Who was studied?
The researchers studied 103 patients with scleroderma lung disease at the Johns Hopkins and University of Maryland Scleroderma Center.
How was the study done?
Some of the patients were treated with cyclophosphamide, depending on their doctor's decision. All of the patients underwent procedures to obtain pieces of lung tissue (biopsies) or lung cells (washings) that could be examined for inflammation. The researchers looked for signs of alveolitis on the lung biopsies or washings. They then compared lung function, which they evaluated by using special breathing tests, and survival among patients who got cyclophosphamide and patients who did not get this drug.
What did the researchers find?
Of the 103 patients, 69 had alveolitis and 34 did not. Thirty-nine of the patients with alveolitis got cyclophosphamide and 30 did not. Patients with alveolitis who got cyclophosphamide did better on the breathing tests and survived longer than those who did not get the drug. Side effects of cyclophosphamide treatment included hair loss, infection, and bleeding into the urinary tract.
What were the limitations of the study?
Patients were not randomly assigned to get or to not get cyclophosphamide. It is possible, therefore, that the doctors may have given the drug to the patients who had the best chances of doing well. Also, there were too few patients to be able to identify which types of patients with scleroderma lung disease were most likely to benefit from treatment with cyclophosphamide.
What are the implications of the study?
Patients with scleroderma lung disease involving inflammation of the lungs who get cyclophosphamide appear to have improvements in their breathing and live longer than similar patients who do not get this drug.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  I Miniati, S Guiducci, M L Conforti, V Rogai, G Fiori, M Cinelli, R Saccardi, S Guidi, A Bosi, A Tyndall, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis Ann Rheum Dis, January 1, 2009; 68(1): 94 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, and V. Rivera A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology, January 1, 2009; 48(1): 49 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Khanna, D. E. Furst, P. J. Clements, D. P. Tashkin, and M. H. Eckman Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis Med Decis Making, November 1, 2008; 28(6): 926 - 937. [Abstract] [PDF]
|
|
|
|
 |
|
 A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Goldin, D. A. Lynch, D. C. Strollo, R. D. Suh, D. E. Schraufnagel, P. J. Clements, R. M. Elashoff, D. E. Furst, S. Vasunilashorn, M. F. McNitt-Gray, et al. High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease Chest, August 1, 2008; 134(2): 358 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Strange and J. R. Seibold Scleroderma Lung Disease: "If You Don't Know Where You Are Going, Any Road Will Take You There" Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1178 - 1179. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Gerbino, C. H. Goss, and J. A. Molitor Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease Chest, February 1, 2008; 133(2): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Baughman and G. Raghu Bronchoalveolar Cellular Analysis in Scleroderma Lung Disease: Does Sutton's Law Hold? Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
|
|
C. Strange, M. B. Bolster, M. D. Roth, R. M. Silver, A. Theodore, J. Goldin, P. Clements, J. Chung, R. M. Elashoff, R. Suh, et al. Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J Clements, M. D Roth, R. Elashoff, D. P Tashkin, J. Goldin, R. M Silver, M. Sterz, J. R Seibold, D. Schraufnagel, R. W Simms, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis Ann Rheum Dis, December 1, 2007; 66(12): 1641 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Tashkin, R. Elashoff, P. J. Clements, M. D. Roth, D. E. Furst, R. M. Silver, J. Goldin, E. Arriola, C. Strange, M. B. Bolster, et al. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1026 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Feghali-Bostwick, C. G. Tsai, V. G. Valentine, S. Kantrow, M. W. Stoner, J. M. Pilewski, A. Gadgil, M. P. George, K. F. Gibson, A. M. K. Choi, et al. Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis J. Immunol., August 15, 2007; 179(4): 2592 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Verrecchia, J. Laboureau, O. Verola, N. Roos, R. Porcher, P. Bruneval, M. Ertault, K. Tiev, L. Michel, A. Mauviel, et al. Skin involvement in scleroderma--where histological and clinical scores meet Rheumatology, May 1, 2007; 46(5): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Swigris, A. L. Olson, A. Fischer, D. A. Lynch, G. P. Cosgrove, S. K. Frankel, R. T. Meehan, and K. K. Brown Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest, July 1, 2006; 130(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, July 1, 2006; 130(1): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Tashkin, R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, D. E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med., June 22, 2006; 354(25): 2655 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez and W. J. McCune Cyclophosphamide for scleroderma lung disease. N. Engl. J. Med., June 22, 2006; 354(25): 2707 - 2709. [Full Text] [PDF]
|
|
|
|
|
|
V Steen Predictors of end stage lung disease in systemic sclerosis Ann Rheum Dis, February 1, 2003; 62(2): 97 - 99. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. McSweeney, R. A. Nash, K. M. Sullivan, J. Storek, L. J. Crofford, R. Dansey, M. D. Mayes, K. T. McDonagh, J. L. Nelson, T. A. Gooley, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes Blood, August 13, 2002; 100(5): 1602 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Crystal, P. B. Bitterman, B. Mossman, M. I. Schwarz, D. Sheppard, L. Almasy, H. A. Chapman, S. L. Friedman, T. E. King Jr., L. A. Leinwand, et al. Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 236 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bouros, A. U. Wells, A. G. Nicholson, T. V. Colby, V. Polychronopoulos, P. Pantelidis, P. L. Haslam, D. A. Vassilakis, C. M. Black, and R. M. du Bois Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1581 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Girgis, M. K. Gugnani, J. Abrams, and M. D. Mayes Partitioning of Alveolar and Conducting Airway Nitric Oxide in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1587 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Luzina, S. P. Atamas, R. Wise, F. M. Wigley, H. Q. Xiao, and B. White Gene Expression in Bronchoalveolar Lavage Cells from Scleroderma Patients Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Sapadin and R. Fleischmajer Treatment of Scleroderma Arch Dermatol, January 1, 2002; 138(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Cyclophosphamide May Provide Benefit in Scleroderma Journal Watch Dermatology, August 1, 2000; 2000(801): 14 - 14. [Full Text]
|
|
|
|
 |
|
 Cyclophosphamide May Provide Benefit in Scleroderma Journal Watch (General), June 30, 2000; 2000(630): 4 - 4. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
